Clinical and Immunological Response to Sublingual Vaccination for the Prevention of Recurrent Urinary Tract Infections in Kidney Transplant Patients

Shabaka, Amir; Manzanara, Virginia Lopez de la; Zapata, Natalia Rosana; Santiago, José Luis; Pérez‐Flores, Isabel; Higuera, Maria de los Angeles Moreno de la; Sánchez‐Ramón, Silvia; Sánchez‐Fructuoso, Ana

doi:10.1097/01.tp.0000543044.21389.51

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other studies evaluating subjects (men and/or women) with complicated UTI, including men with prostatitis, 20 neurogenic bladder, 21 autoimmune disease and treatment-mediated immunosuppressed patients, 22 chronic renal disease and kidney transplant, [23][24][25][26] lymphoproliferative disorders, 27 frail elderly, 28,29 children, 30 and post-surgery, 31 consistently reported favorable UTI-free rates ranging from 30-50%, significant UTI reduction rates after Uromune treatment, and/ or improved quality of life (Table 3). Moreover, one study addressed that re-vaccination a year-and-a-half later, as well as being safe, may confer further benefit to individuals with rUTI.…”

Section: Prevention Of Ruti In Other Populationsmentioning

confidence: 99%

Could sublingual vaccination be a viable option for the prevention of recurrent urinary tract infection in Canada? A systematic review of the current literature and plans for the future

Nickel

2020

CUAJ

View full text Add to dashboard Cite

(word count: 248) Introduction: We conducted a systematic review to examine the role of a novel sublingual vaccine – Uromune – for prevention of recurrent urinary tract infection (rUTI) to understand its potential role for Canadian women suffering from rUTI. Methods: Databases were searched for studies published from 2010-2020 that investigated use of Uromune in management of rUTI. Only original clinical studies which included use of Uromune as prophylaxis for uncomplicated rUTI in women that included UTI-free rate following initiation of vaccine as an outcome were included. Results: Of 73 publications related to Uromune and UTIs, 19 unique clinical studies were identified evaluating Uromune for prevention of rUTI. Five studies met our inclusion criteria for primary review. These included 1,408 women treated with Uromune. In 2 retrospective comparative studies, subjects treated with Uromune daily for 3 months had significantly higher UTI-free rates (35 to 90%) than subjects treated with 6 months of antibiotic prophylaxis (0% in 499 women in total) over 15 months (p<0.001 for both studies). In 3 prospective uncontrolled studies, UTI-free rates for subjects treated with Uromune ranged from 33 to 78% over 9-24 months. No major safety issues were identified in these trials. Additional unique studies evaluating Uromune for rUTI that did not meet our criteria added consistent confirmation of the potential efficacy and safety of Uromune to prevent rUTI. Conclusions: Although these findings require confirmation in currently active prospective clinical studies, including a randomized placebo-controlled trial, Uromune may be an alternative to antibiotics to prevent rUTI in Canadian women.

show abstract

Section: Prevention Of Ruti In Other Populationsmentioning

confidence: 99%

Could sublingual vaccination be a viable option for the prevention of recurrent urinary tract infection in Canada? A systematic review of the current literature and plans for the future

Nickel

2020

CUAJ

View full text Add to dashboard Cite

show abstract

“…In studies examining the impact of MV140 on men with rUTIs, one [ 30 ] enrolled 136 men who experienced a 30% UTI-free rate at a 6-month follow-up, while another smaller study [ 34 ] described 14 men with rUTIs who reported a UTI-free rate of 71% at 12 months (10/14). Other studies evaluating subjects (men and/or women) with complicated UTIs including men with prostatitis [ 35 ], neurogenic bladder [ 36 ], autoimmune disease and treatment-mediated immunosuppressed patients [ 37 ], chronic renal disease and kidney transplant [ 38 , 39 , 40 , 41 ], lymphoproliferative disorders [ 42 ], frail elderly [ 43 , 44 ], children [ 45 ] and postsurgery [ 46 ] consistently reported favorable UTI-free rates ranging from 30–50% and significant UTI reduction rates and/or improved quality of life after MV140 treatment.…”

Section: Effectiveness Of Mv140 In Other Populations Of Patients With...mentioning

confidence: 99%

An Effective Sublingual Vaccine, MV140, Safely Reduces Risk of Recurrent Urinary Tract Infection in Women

Nickel

d’Oiron

2023

Pathogens

View full text Add to dashboard Cite

Uncomplicated recurrent urinary tract infections (rUTIs) in women are associated with episodic bothersome symptoms and have a significant impact on the mental and physical quality of life. Treatment with antibiotics (short- and long-term dosing) results in acute and chronic side effects and costs and promotes general antibiotic resistance. Improved nonantibiotic management of rUTI in women represents a true, unmet medical need. MV140 is a novel sublingual mucosal-based bacterial vaccine developed for the prevention of rUTI in women. Based on observational, prospective, and randomized placebo-controlled studies, MV140 has been shown to safely prevent (or reduce the risk of) UTIs, reduce antibiotic use, overall management costs, and patient burden while improving the overall quality of life in women suffering from rUTIs.

show abstract

Urinary Tract Infections in Kidney Transplant Patients

Medina-Polo,

Schneidewind,

Stangl

et al. 2024

Guide to Antibiotics in Urology

View full text Add to dashboard Cite

Clinical and Immunological Response to Sublingual Vaccination for the Prevention of Recurrent Urinary Tract Infections in Kidney Transplant Patients

Cited by 3 publications

References 0 publications

Could sublingual vaccination be a viable option for the prevention of recurrent urinary tract infection in Canada? A systematic review of the current literature and plans for the future

Could sublingual vaccination be a viable option for the prevention of recurrent urinary tract infection in Canada? A systematic review of the current literature and plans for the future

An Effective Sublingual Vaccine, MV140, Safely Reduces Risk of Recurrent Urinary Tract Infection in Women

Urinary Tract Infections in Kidney Transplant Patients

Contact Info

Product

Resources

About